The effect of anti-recurrent treatment of uterine fibroid with mifepristone on the state of the mammary glands in women of reproductive age
Vladislava Novikova (RU), Vadim Khorolskiy (RU)
[Novikova] Kuban State Medical University, [Khorolskiy] Kuban State Medical University
Objective: To evaluate the effect of anti-recurrent treatment of uterine fibroid with mifepristone on the state of the mammary glands in women of reproductive age. Methods – Patient(s). A prospective non-randomized cohort study of 110 women of reproductive age in Regional Clinical Hospital N2 of Krasnodar in 2012-2016 , who after myomectomy as anti-recurrent therapy appointed Mifepristone (Gynestril) at a dose of 50 mg per day continuously for 3 months. Before prescribing mifepristone, after its cancellation, and 3 months later was performed the control of dyshormonal mammary dysplasia (DMD), endometrial thickness. Result(s). The average age of women 29,45±0,38 (21-40) y, the duration of fibroids 3,3±0,26 (0-15) y. Age of newly diagnosed of fibroids 26±0,24 (21-34) y. The number of remote fibroids 1,39±0,07 (1-5). The size of the maximum remote fibroids 52,38±2,31 mm. In 28,18% (n=31) of women were significant increase in endometrial thickness from initial 10,60±0,38 mm to 13,19±0,6 mm at the end of the treatment (p<0.05). After subsequent 3 months identified spontaneous normalization of endometrial thickness up to 10,78±0,26 mm (p <0.05), that was comparable with initial (p>0,05). The examination of mammary glands revealed that initially 61,82% (n=68) of women had subjective symptoms (soreness, swelling) of DMD, objective ultrasound evidence in 47,27% (n=52) women. In a dominant number of women had evidence of diffuse changes in the mammary gland, only 22,73% (n=25) had a cyst diameter less than 1.5 mm. After mifepristone (50 mg) treatment reduced the number of women with subjective symptoms (up to 31,82%, n=35 (p <0.05) and ultrasound signs (19,84%, n=28 (p 0, 05) of DMD. Conclusion. Anti-recurrent treatment of uterine fibroid with mifepristone associated with a reduction in the frequency of clinical of dyshormonal mammary dysplasia in women of reproductive age.